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OBJECTIVE — Although statin therapy reduces cardiovascular risk, its relationship with the
development of diabetes is controversial. The ﬁrst study (West of Scotland Coronary Prevention
Study [WOSCOPS]) that evaluated this association reported a small protective effect but used
nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-
testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible
effect of statin therapy on incident diabetes.
RESEARCH DESIGN AND METHODS — A systematic literature search for random-
ized statin trials that reported data on diabetes through February 2009 was conducted using
speciﬁc search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothe-
sis-testing data were available from the Heart Protection Study (HPS), the Long-Term Interven-
tion with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT), the Justiﬁcation for the Use of Statins in Prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study
in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9
years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as
risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores
were assessed with the Q and I
2 statistic.
RESULTS — Inthemeta-analysisofthehypothesis-testingtrials,weobservedasmallincrease
in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials.
However,thisestimatewasattenuatedandnolongersigniﬁcantwhenthehypothesis-generating
trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in signiﬁcant heterogeneity
(Q 11.8 [5 d.f.], P  0.03, I
2  57.7%).
CONCLUSIONS — Although statin therapy greatly lowers vascular risk, including among
thosewithandatriskfordiabetes,therelationshipofstatintherapytoincidentdiabetesremains
uncertain. Future statin trials should be designed to formally address this issue.
Diabetes Care 32:1924–1929, 2009
T
heroleofstatinsinprimaryandsec-
ondarypreventionofcardiovascular
disease(CVD),includingamongpa-
tients with type 2 diabetes, is well estab-
lished.However,therelationshipofstatin
therapytoincidenttype2diabetesiscon-
troversial. In the ﬁrst study that evaluated
this association using the West of Scot-
land Coronary Prevention Study
(WOSCOPS) published in 2001, prava-
statin at 40 mg/day was reported to be
associated with a 30% risk reduction for
incident diabetes, although the upper
bound of the 95% CI for that observation
was 0.99 (1). The WOSCOPS, however,
required an increase in fasting glucose
36mg/dlabovebaselinefordiagnosisof
incident diabetes in addition to the stan-
dard diagnostic criteria of fasting glucose
126 mg/dl. Subsequent hypothesis-
testing analyses from randomized trials of
pravastatin,simvastatin,atorvastatin,and
rosuvastatinhavesuggestedeithernorisk
or a slight hazard; in one head-to-head
comparison, use of atorvastatin 80 mg
was slightly more likely than 40 mg prav-
astatin to result in incident diabetes, data
which have suggested to some that this
effectmayrelatetodoseorpotency(2–6).
Further, in the recent Justiﬁcation for the
UseofStatinsinPrevention:anIntervention
Trial Evaluating Rosuvastatin (JUPITER),
statin treatment was associated with a
small increase in physician-diagnosed di-
abetes, although without an increase in
glucose levels (relative risk [RR] 1.25
[95% CI 1.05–1.49]). Given these uncer-
tainties, we conducted a meta-analysis of
availabletrialstoidentifywhatrole,ifany,
statin therapy might have in the develop-
ment of type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Search strategy, inclusion criteria,
and data extraction
We searched the Medical Literature Anal-
ysis and Retrieval System Online
(MEDLINE) and Cochrane databases for
randomizedclinicaltrials(frominception
to February 2009) using the following
medical subject heading terms diabetes:
statins, HMG CoA reductase inhibitor,
pravastatin, atorvastatin, lovastatin, sim-
vastatin, cerivastatin, rosuvastatin, and
ﬂuvastatin. To increase the sensitivity of
our search, eligible studies were cross-
referenced using the Science Citation In-
dex (SCI). We also reviewed recently
presented data at national and interna-
tional meetings. Additionally, we looked
through Internet-based sources of in-
formation (www.cardiosource.com, www.
google.com, www.clinicaltrialresults.org,
www.theheart.org, and www.tctmd.com).
We also corresponded with experts in the
ﬁeld,andinthecaseofeligiblestatintrials
where diabetes incidence data were not
reported in the published article, we con-
tacted the investigators directly for this
information.
Our meta-analysis included all ran-
domized placebo-controlled trials that
have reported data on incidence of type 2
diabetes during follow-up. To generate
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mary and secondary cardiovascular pre-
vention trials but excluded registries and
other nonrandomized analyses as well as
studieswherepatientshadpreexistingdi-
abetes or where one statin was compared
with another. In addition, we excluded
studies where other lipid-lowering medi-
cations were used either in lieu of or in
addition to statins. Studies examining
the role of statins on nonclinical out-
comes where no data on diabetes was
availablewereexcluded,aswerestudies
limited to specialized noncardiovascu-
lar populations.
The primary clinical outcome of in-
terest was the incidence of new-onset di-
abetes. Because this was not uniformly
diagnosed, the different deﬁnitions in
each trial were separately recorded. Phy-
sician- or patient-reported new-onset di-
abetes was permissible.
Two independent reviewers (S.N.R.
and D.J.K.) abstracted the following vari-
ables in each study: 1) patient demo-
graphics, 2) number of patients who
experienced and who were at risk for the
outcome of diabetes, 3) type and dose of
statin used, 4) criteria used for diagnosis
of diabetes, and 5) duration of follow-up.
Discrepancies were resolved through a
third reviewer (J.C.).
The methodological quality of the in-
cluded randomized clinical trials was as-
sessedusingcriteriasuggestedbyJadadet
al. (7). Because all studies met at least
three of the ﬁve criteria, they were judged
to be of high quality. No formal scoring
method was therefore used.
Statistical analyses
Onanaprioribasis,weelectedtoperform
a hypothesis-testing meta-analysis that
excluded the initial observations from
WOSCOPS as well as an analysis of all
available data including the hypothesis-
generating WOSCOPS data. Summary
RRs with 95% CIs were computed for
each outcome. RRs were deﬁned as the
risk of cumulative incidence of diabetes
among those who received statins com-
pared with that among those who re-
ceived placebo. The summary RR and its
95% CI were estimated using the DerSi-
monian and Laird method for random ef-
fects (8). The random-effects model is
reported in the text and ﬁgures. To assess
heterogeneity across studies, we used the
Cochran Q statistic based on the pooled
RR by Mantel-Haenszel and measured in-
consistency (I
2; the percentage of total
varianceacrossstudiesattributabletohet-
erogeneity rather than chance) of treat-
ment effects across trials (9). We used
Begg and Mazumdar’s funnel plot to as-
sess for publication bias (10). All P values
were two tailed, and P  0.05 was con-
sidered statistically signiﬁcant. All analy-
ses were performed using STATA
software version 10.0 (STATA, College
Station, TX) and Comprehensive Meta-
Analysis software version 2 (Biostat,
Englewood, NJ).
RESULTS— Six trials met inclusion
criteria (Figure 1 and Table 1) and in-
cluded 57,593 randomized patients (n
for statin intervention  28,842; n for
placebo  28,751). Three studies
(WOSCOPS, the Anglo-Scandinavian
Cardiac Outcomes Trial [ASCOT], and
the JUPITER) were primary cardiovascu-
lar prevention trials, whereas three were
secondary prevention trials (the Heart
Protection Study [HPS], the Long-Term
Intervention with Pravastatin in Ischemic
Disease [LIPID] Study, and the Con-
trolled Rosuvastatin Multinational Study
in Heart Failure [CORONA]). Two of the
trials used 40 mg/day pravastatin
(WOSCOPSandLIPID),tworosuvastatin
(CORONA 10 mg/day and JUPITER 20
mg/day), one 40 mg/day simvastatin
(HPS), and one 10 mg/day atorvastatin
(ASCOT).Clinicalfollow-uprangedfrom
a median 1.9 years (JUPITER) to over 5
years (LIPID), with a weighted mean du-
ration of follow-up of 3.9 years. The pri-
mary analysis of data from these trials
suggested an 8–44% risk reduction in
CVD incidence comparing statin group
with placebo group. Because the study
populations for each trial differed con-
siderably, we have provided the base-
linecharacteristicsofindividualtrialsin
Table 2.
Together, the six studies reported a
total of 2,082 incident cases of diabetes
during follow-up. The criteria for ascer-
tainmentoftype2diabetesvariedinthese
studies (Table 1). Three studies (HPS,
CORONA, and JUPITER) relied on phy-
sician-reported diagnosis and treatment
for diabetes, whereas the other three
(WOSCOPS, ASCOT, and LIPID) also in-
corporated standardized diagnostic crite-
ria based on plasma glucose levels or oral
glucose tolerance test. In addition to the
standardized fasting glucose criteria
(126 mg/dl plasma glucose on two oc-
casions), the WOSCOPS trial also re-
quired a 2 mmol/l (or 36 mg/dl)
increase in fasting glucose level from
baseline for diabetes diagnosis.
Among the individual studies, four of
the studies reported a null association be-
tween statin use and diabetes risk. One
study(WOSCOPS)reportedastatistically
Figure 1—Flowchart of selection of studies for inclusion in the meta-analysis.
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on diabetes incidence (RR 0.70 [95% CI
0.50–0.99]; P  0.042), whereas one
(JUPITER) reported a signiﬁcant positive
association (1.25 [1.05–1.49]; P  0.01).
In a meta-analysis of the ﬁve hypoth-
esis-testing trials, the summary RR for in-
cident diabetes was 1.13 (95% CI 1.03–
1.24; P  0.007) (Fig. 2). This
corresponded to a risk difference of 0.5%
(0.2–0.8). No signiﬁcant heterogeneity
was observed in this latter analysis (Q sta-
tistic  4.06 [4 d.f.], P  0.40, I
2 
1.6%), and we observed no evidence in
these hypothesis-testing analyses of any
interaction by speciﬁc drug. However,
when the hypothesis-generating
WOSCOPS was included in the analyses,
the summary RR from the random-effects
model was 1.06 (95% CI 0.93–1.23; P 
0.38) (Fig. 2). This analysis also revealed
signiﬁcant heterogeneity (Q statistic 
11.8 [5 d.f.], P  0.03, I
2  57.7%)
driven largely by the WOSCOPS data.
Further, there was no evidence of publi-
cation bias (P  0.15).
CONCLUSIONS — In the ﬁrst study
that evaluated the statin-diabetes associa-
tion, Freeman et al. (1) reported an in-
verse association between pravastatin use
and diabetes incidence in the WOSCOPS
(RR 0.7 [95% CI 0.55–0.99]) but used
additional nonstandardized criteria for
diabetes diagnosis. Subsequent statin tri-
als did not conﬁrm this protective effect,
and in the recent JUPITER a small but
signiﬁcant increase in physician-reported
diabetes was reported among statin users
compared with those taking placebo, al-
though in the absence of any effect on
glucose levels (6). As suggested here, and
contrary to the hypothesis-generating
data from WOSCOPS, in this meta-
analysis of ﬁve hypothesis-testing trials a
small but statistically signiﬁcant increase
in diabetes incidence may be associated
with statin use, which does not appear to
be drug or dose speciﬁc. This potential
effect was attenuated and no longer sig-
niﬁcant in meta-analysis of all available
data including WOSCOPS.
Our data suggest that continued ef-
fortstounderstandrelationshipsbetween
statin therapy and diabetes are needed,
both in future clinical trials and in terms
of laboratory exploration. Understanding
the potential mechanisms that may ex-
plain this effect will require direct exper-
imental effort. One possible explanation
is that in addition to CVD protective ef-
fects, statin therapy may interfere with
normal glucose metabolism (11). In this
regard, both in vitro and in vivo data sug-
gest that atorvastatin decreases adipocyte
maturation and results in a decline in ex-
pression of GLUT4 and upregulation of
GLUT1 in cultured preadipocytes and in
mice(12).Thisresultsinamarkedreduc-
tion in insulin-mediated cellular glucose
uptake caused by decreased insulin sen-
sitivity, which may possibly result in ex-
acerbation of glucose intolerance (13). It
isalsopossiblethatstatin-inducedinsulin
resistance may result from inhibition of
isoprenoid biosynthesis, an intermedi-
ate product in cholesterol formation,
becausee these effects can be reversed
by the isoprenoid precursor mevalonate
(12,14). Furthermore, in addition to in-
ducing insulin resistance, statin therapy
may also directly affect insulin secretion.
From this perspective, the most relevant
experimental data in rats have demon-
strated that when pancreatic -cells are
incubatedwithstatins,insulinsecretionis
reduced due to inhibition of glucose-
stimulated increase in free cytoplasmic
Ca
2 and L-type Ca
2 channels (15).
Similar ﬁndings were also reported in an-
other study using a -cell line, MIN6
cells, where investigators demonstrated
that high doses of lipophilic but not
hydrophilicstatinsdecreaseinsulinsecre-
tion, either due to hydroxymethylglu-
taryl-CoA inhibition or cytotoxicity (16).
Another possibility is that statins may un-
cover diabetes in high-risk individuals,
which on a population basis could result
in modest hazard. For example, within
the JUPITER, 77% of those in the inter-
vention arm who developed diabetes in
the follow-up had impaired fasting glu-
cose at study entry; this is not surprising
because JUPITER, unlike all prior statin
trials, enrolled subjects on the basis of el-
evated high-sensitivity C-reactive pro-
tein, an inﬂammatory biomarker that is
associated with increased diabetes risk.
Balancing this modest risk to major mac-
rovascular beneﬁts is important because
thisJUPITERsubgroupalsowasobserved
tohavelargeandhighlysigniﬁcantreduc-
tionsinmyocardialinfarction,stroke,and
cardiovascular death associated with ro-
suvastatin allocation.
A few studies have suggested that sta-
tin use may result in an increase in A1C
levels (2,17), although these effects have
been quite small. Human data also raise
the possibility that lipophilic and hydro-
philicstatinsmayhavedifferenteffectson
glucose (18). In this regard, the Pravasta-
tin or Atorvastatin Evaluation and Infec-
tion Therapy–Thrombolysis in
Myocardial Infarction 22 (PROVE-IT
TIMI 22) trial reported that although
treatment with both 80 mg atorvastatin
and 40 mg pravastatin were both associ-
ated with a small increase in A1C (atorva-
statin 0.37% and pravastatin 0.18%),
atorvastatin signiﬁcantly increased risk of
developing an A1C 6% compared with
pravastatin(RR1.84[95%CI1.52–2.22];
P  0.0001) (19). Similarly, in two Japa-
nese studies among nondiabetic adults,
atorvastatin but not pravastatin was asso-
Table 2—Baseline characteristics of study population in the included trials
WOSCOPS HPS LIPID ASCOT CORONA JUPITER
Age (years) 55.2 63.9 62.0 63.1 73.0 66.0
Men (%) 100.0 75.3 83.0 81.2 76.0 61.8
Caucasian (%) NA NA NA 94.7 NA 71.2
Diabetes at baseline (%) 1.2 29.0 11.9 24.6 29.5 0
BMI (kg/m
2) 26.0 27.6 NA 28.7 27.0 28.4
Prior MI (%) 0 41.0 64.0 0 60.0 0
LDL cholesterol (mg/dl) 192.0 131.5 152.5 132.6 138.5 108.0
HDL cholesterol (mg/dl) 44.0 41.0 36.3 50.7 48.4 49.0
Triglycerides (mg/dl) 163.0 186.0 136.2 146.9 178.0 118.0
FBG (mg/dl) 85.0 NA 101.0 111.7 NA 94.0
A1C (%) NA NA NA NA NA 5.7
FBG measurement laboratory Central Central Central Central Central Central
Concomitant medications (%)
-Blockers NA NA 47 NA 75 NA
Thiazides NA NA NA NA 13 NA
ACEI/ARB NA NA 16 NA 91.5 NA
Data are means for continuous variables, except for JUPITER, where median values were reported. ACEI,
ACE inhibitor; ARB, angiotensin receptor blocker; FBG, fasting blood glucose; MI, myocardial infarction;
NA, not available.
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(12,18).
Certain limitations of our meta-
analysis warrant consideration. First, our
analysis was restricted to the few clinical
trials that reported data on diabetes inci-
dence in statin trials; other statin trials
may have data on diabetes available that
can augment these analyses. Second,
none of these clinical trials were con-
ducted with diabetes as the primary out-
come and therefore were not statistically
powered to evaluate this outcome. Our
data are also limited in that the diagnostic
criterion for diabetes varied among the
trials and often was based on physician
report rather than systematic surveil-
lance.Finally,wecannotruleoutthepos-
sibility that the increased risk of diabetes
amongstatinusersmaybeduetosurvival
bias related to better survival in the inter-
vention group. We conducted meta-
analysis both with and without the initial
hypothesis-generating WOSCOPS for
two important reasons. First, as indicated
earlier, WOSCOPS used additional non-
standardized criteria for diabetes diagno-
sis. Second, the practice of conducting
summary analysis after excluding the
chronologically ﬁrst (hypothesis-
generating) study is commonly used in
meta-analysis. In fact, Fleming et al. (20)
recently suggested that this approach is
important to avoid any regression-to-the-
mean effect and to provide the most un-
biased estimates of effect. Furthermore,
when we additionally conducted a meta–
regression analysis of the included trials,
both age (P  0.029) and female sex (P 
0.002) were signiﬁcantly associated with
an increased risk of statin-induced diabe-
tes.Whenbothageandsexwereincluded
together, only sex (elevated risk among
women) remained signiﬁcant (P 
0.044). WOSCOPS was the only trial that
included only men and hence may be
consideredasanoutlierforthisadditional
reason. Finally, unlike the analysis that
excluded WOSCOPS, there was signiﬁ-
cant heterogeneity between trials when
WOSCOPS was included in the analysis.
Figure 2—Meta-analysis of clinical trials evaluating the effects of statins on diabetes risk.
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sive meta-analysis is also meaningful, un-
derscoring the need for future statin trials
to formally investigate this issue.
In conclusion, in the hypothesis-
testing component of this meta-analysis,
wefoundnoevidenceforaprotectiverole
of statin treatment on incident diabetes
butratherobservedasmallbutsigniﬁcant
increase in risk. By contrast, this effect
was attenuated and no longer signiﬁcant
in a meta-analysis that included all avail-
able evidence, including the original hy-
pothesis-generating data. Given this
uncertainty, ongoing efforts in clinical
and experimental settings should con-
tinue to investigate these relationships. In
the meantime, the clear beneﬁts of statins
on CVD likely outweigh any potential
detrimental effects on glucose metabo-
lism and diabetes risk.
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